M&R Capital Management Inc. lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,789 shares of the medical instruments supplier’s stock after selling 300 shares during the quarter. M&R Capital Management Inc.’s holdings in Becton, Dickinson and were worth $1,330,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Two Sigma Securities LLC acquired a new stake in Becton, Dickinson and in the first quarter valued at approximately $493,000. Level Four Advisory Services LLC grew its position in Becton, Dickinson and by 23.1% in the first quarter. Level Four Advisory Services LLC now owns 3,634 shares of the medical instruments supplier’s stock valued at $666,000 after acquiring an additional 683 shares in the last quarter. Sii Investments Inc. WI grew its position in Becton, Dickinson and by 14.1% in the first quarter. Sii Investments Inc. WI now owns 1,700 shares of the medical instruments supplier’s stock valued at $311,000 after acquiring an additional 210 shares in the last quarter. Signaturefd LLC grew its position in Becton, Dickinson and by 17.0% in the first quarter. Signaturefd LLC now owns 2,361 shares of the medical instruments supplier’s stock valued at $433,000 after acquiring an additional 343 shares in the last quarter. Finally, Cypress Capital Group grew its position in Becton, Dickinson and by 84.6% in the first quarter. Cypress Capital Group now owns 4,615 shares of the medical instruments supplier’s stock valued at $847,000 after acquiring an additional 2,115 shares in the last quarter. 88.46% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have issued reports on BDX. Barclays reaffirmed an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a research note on Tuesday, October 31st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Finally, BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $217.08.

In related news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

Becton, Dickinson and Company (NYSE BDX) opened at $218.92 on Thursday. The stock has a market capitalization of $49,943.21, a PE ratio of 23.08, a P/E/G ratio of 1.72 and a beta of 1.07. Becton, Dickinson and Company has a fifty-two week low of $161.29 and a fifty-two week high of $229.68. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. Becton, Dickinson and’s revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.12 earnings per share. analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a dividend of $0.75 per share. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s payout ratio is presently 62.80%.

COPYRIGHT VIOLATION WARNING: This news story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://theolympiareport.com/2017/12/07/becton-dickinson-and-company-bdx-shares-sold-by-mr-capital-management-inc.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.